Article

Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors be a Game Changer?

2022-09-20

Abstract excerpt

Most pivotal clinical trials in advanced non-small cell lung cancer (NSCLC) have excluded patients with poor performance status (PS), and data on the efficacy and safety of pharmacotherapy have not been fully accumulated. For NSCLC patients with PS 2 and without druggable genetic alterations, monotherapy with cytotoxic agents or carboplatin-based combination therapy is usually administered based on the results of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 89dd0329-38bb-5e72-9a7f-fccdecc9e32d
DOI: 10.20944/preprints202209.0296.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors be a Game Changer?DOI 10.20944/preprints202209.0296.v1Read

Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)Semantic proximity Read

Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.Semantic proximity Read

[Checkpoint inhibitors in the decision-making algorithm of advanced non-small-cell lung cancer.]Semantic proximity Read

NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status.Semantic proximity Read

Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.Semantic proximity Read

Update in Immunotherapy for Advanced Non-small Cell Lung Cancer: Treatment Sequencing and Best ChoicesSemantic proximity Read

The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.Semantic proximity Read

Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.Semantic proximity Read